Jason D'Orlando | Source | Vice President, Pharma Sector at Turner & Townsend
Jason D'Orlando
Jason is a high-performing program management executive with over 20 years of experience in the pharmaceutical, construction, and engineering industries. He manages large scale programs, project control teams and leading complex rollouts on projects from $250M to $3B. Jason is expert at building, optimizing, and managing large teams focused on maximizing business results in cost, schedule, risk, and change management. He is also a skilled strategist who transforms strategic plans into workable solutions, bringing complex project, finance, and program management tracks together to deliver client expectations. Jason is accomplished at relationship building and partnering to drive project and portfolio performance.
-
Turner & Townsend
Vice President, Pharma Sector
-
Big pharma urged to share plant construction data because projects are late and over budget - News - GCR
Construction consultant Turner & Townsend is calling on pharmaceutical companies to share data on their ......
Article -
Report: Early construction planning needed to speed drugs, vaccines to market
Rushing pharmaceutical projects throughthe planning processends up costingtime and money, according to global consultancy Turner & Townsend.
Article -
Turner & Townsend releases 2021 Pharma Sector Construction Benchmark Analysis - PharmaVOICE
Turner & Townsend releases 2021 Pharma Sector Construction Benchmark Analysis New study benchmarks cost and time to build, suggests opportunities to improve speed-to-market of facilities and lifesaving pharmaceuticals. January 21, 2021 Fast Facts: Global professional services firm, Turner & Townsend, analyzed a selection of 20 large scale (>100 million USD) pharmaceutical construction projects completed …
Article
-
By planning more thoroughly at the earliest stages of capital projects, and applying robust industry benchmarks, pharmaceutical companies can better avoid damaging cost and schedule overruns at a time when these simply cannot be afforded. The industry needs to come together to improve visibility and predictability on cost and risks if we are to deliver more manufacturing capability for the global pharmaceutical sector at pace.
